Equities Analysts Offer Predictions for Elevation Oncology, Inc.’s Q1 2024 Earnings (NASDAQ:ELEV)

Elevation Oncology, Inc. (NASDAQ:ELEVFree Report) – Analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of Elevation Oncology in a research report issued on Monday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings of ($0.32) per share for the quarter. The consensus estimate for Elevation Oncology’s current full-year earnings is ($1.22) per share. Leerink Partnrs also issued estimates for Elevation Oncology’s Q2 2024 earnings at ($0.34) EPS, Q3 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.17) EPS, FY2025 earnings at ($1.10) EPS and FY2026 earnings at ($1.07) EPS.

Separately, Wedbush reissued an “outperform” rating and set a $5.00 target price on shares of Elevation Oncology in a report on Monday, November 6th.

View Our Latest Stock Analysis on Elevation Oncology

Elevation Oncology Trading Down 1.0 %

Elevation Oncology stock opened at $3.09 on Thursday. Elevation Oncology has a 52 week low of $0.36 and a 52 week high of $5.89. The stock has a 50-day moving average price of $1.50 and a 200 day moving average price of $0.99. The company has a quick ratio of 12.99, a current ratio of 12.99 and a debt-to-equity ratio of 0.48.

Hedge Funds Weigh In On Elevation Oncology

Several institutional investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in Elevation Oncology during the second quarter valued at $30,000. Virtu Financial LLC purchased a new position in shares of Elevation Oncology during the 2nd quarter valued at approximately $31,000. JPMorgan Chase & Co. grew its stake in Elevation Oncology by 427.1% in the 1st quarter. JPMorgan Chase & Co. now owns 22,347 shares of the company’s stock valued at $42,000 after acquiring an additional 18,107 shares during the period. Annandale Capital LLC increased its holdings in Elevation Oncology by 66.7% in the 4th quarter. Annandale Capital LLC now owns 50,000 shares of the company’s stock worth $48,000 after acquiring an additional 20,000 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in Elevation Oncology by 53.0% during the first quarter. Renaissance Technologies LLC now owns 25,400 shares of the company’s stock worth $64,000 after acquiring an additional 8,800 shares during the period. 83.70% of the stock is owned by hedge funds and other institutional investors.

About Elevation Oncology

(Get Free Report)

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.

See Also

Earnings History and Estimates for Elevation Oncology (NASDAQ:ELEV)

Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.